Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Cash for care: a simple incentive to keep HIV patients on track

NCT ID NCT05373095

Disease control Sponsor: University of California, Berkeley Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 14, 2026 · Last updated Aug 14, 2026

Summary

This trial tests whether offering small cash payments to people living with HIV, when they attend counseling sessions and clinic visits, can help them stay engaged in care and achieve viral suppression. Participants are adults identified as high risk for dropping out of care at two health facilities in Tanzania. Half will receive standard HIV care, while the other half will also receive up to three cash transfers of about $10 each, paired with enhanced adherence counseling. The study will measure how many participants maintain viral suppression at 12 months.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Conditional cash transfers and adapted adherence counseling
What this could lead to
If effective, this approach could offer a simple, scalable way to keep people with HIV engaged in care and improve long-term health outcomes.
What could go wrong
The trial is relatively small and the cash incentive is modest, so the effect may be limited or not generalizable to other settings. Success depends on participants' willingness to attend sessions and adhere to treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

692 people

The number who actually took part.

Started

Oct 2023

Finished

Apr 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. PLHIV on ART; 2. Age 18 years or older; 3. Phone ownership OR consistent phone access; 4. Not already enrolled in/currently attending enhanced adherence counseling sessions at the facility 5. Living in Geita Region and intends to receive care at a study facility for the next 12 months; 6. Classified as "high-risk" for loss to follow-up (LTFU) from HIV care, and 7. Provides written informed consent for participation

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HIV (human immunodeficiency virus) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

AIDS HIV infectious disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HIV (human immunodeficiency virus)

Contacts and locations

Locations

  • Geita Regional Referral Hospital

    Geita, Tanzania

  • Geita Town Council Hospital

    Geita, Tanzania

  • Katoro Health Center

    Katoro, Tanzania

  • Nyankumbu Health Center

    Geita, Tanzania

More trials for these conditions

Other studies related to the condition(s) this trial covers.